FIELD: medicine; surgery.;SUBSTANCE: cost-effectiveness analysis of antihypertensive pharmacotherapy results is ensured by formula:;Therein is profitability that is cost-effectiveness of antihypertensive pharmacotherapy results, in points. E is clinical effectiveness of antihypertensive therapy: E=1, if desired systolic and diastolic pressures are measured up; E=2, if desired systolic arterial pressure is measured up, while diastolic arterial pressures is not, or any arterial pressure is reduced by 20% and more of the reference value, and desired arterial pressure is not measured up though; E=3, if desired systolic and diastolic arterial pressures are not measured up, or any arterial pressure is reduced by less than 20% of the reference value. O(neg) is deterioration after antihypertensive therapy being performed comparatively to any previous monitored laboratory parametre. S(neg) is health deterioration noticed by the patients in relation to antihypertensive therapy being performed. O(pos) is the absence of deterioration or recorded improvement comparatively to any previous monitored laboratory parametre. S(pos) is the absence of health deterioration or health improvement noticed by the patients in relation to antihypertensive therapy being performed. If factors meeting the conditions of criteria O(neg), S(neg), O(pos), S(pos) are observed, 1 point is assigned to the respective criterion, while said factors are not observed, 0 points are assigned. t is intake multiplicity of each antihypertensive agent a day. mmax is a maximum daily dose of each antihypertensive agent. n is a number of taken antihypertensive agents. Cv is a unit price of each antihypertensive agent in roubles per on the day of purchase. d1 is amount of reactant in a daily dose of each antihypertensive agent, mg; v is a quantity of tablets in a case; d is amount of reactant in a tablet for each antihypertensive agent. The estimated profitability not exceeding 1 point indicates a good therapy, while adequate therapy is interpreted with profitability 1 to 10 points, and 10 points and more show inadequate therapy.;EFFECT: optimisation of pharmacotherapy expenses for the patients suffering from hypertension.;1 ex
展开▼
机译：领域：医学;物质：抗高血压药物治疗结果的成本-效果分析可通过以下公式确保：其中有盈利能力，即抗高血压药物治疗结果的成本-效果。 E是降压治疗的临床效果：E = 1，如果需要的话可以测量收缩压和舒张压; E = 2，如果向上测量了所需的收缩期动脉压，而未测量到舒张期动脉压，或者任何动脉压降低了参考值的20％以上，并且仍未测量到所需的动脉压; E = 3，如果没有测量到所需的收缩压和舒张压，或者任何动脉压降低不到参考值的20％。 O （neg）是进行降压治疗后与以前监测的实验室参数相比恶化的指标。 S（neg）是患者在进行降压治疗时注意到的健康恶化。 O （pos）是相对于任何先前监测的实验室参数而言，没有恶化或记录的改进。 S （pos）是指患者在进行降压治疗时没有注意到健康恶化或健康改善。如果因子满足条件O （neg），S （neg），O （pos），S （pos） 被观察到，将1分分配给相应的标准，而未观察到上述因素，则给0分。 t是每天每种降压药的摄入量倍数。 m max 是每种降压药的最大每日剂量。 n是服用的多种降压药。 C v 是购买之日每种降压药的卢布单价。 d 1 是每种降压药每日剂量中的反应物量，mg; v是一个案件中的药片数量; d是每种抗高血压药在片剂中反应物的量。估计的获利能力不超过1分表示一种良好的治疗方法，而充分的治疗方法则被解释为获利能力为1到10分，而10分或更高的得分则表明治疗不充分。效果：优化高血压患者的药物治疗费用。
展开▼
